Abstract
New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.
| Original language | English |
|---|---|
| Article number | 59 |
| Journal | Current Treatment Options in Oncology |
| Volume | 17 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 1 2016 |
Fingerprint
Keywords
- Antiangiogenic agents
- Immunotherapy
- Non-small-cell lung cancer
- Second line
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Cite this
From 2000 to 2016 : Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? / D’Argento, Ettore; Rossi, Sabrina; Schinzari, Giovanni; Strippoli, Antonia; Basso, Michele; Cassano, Alessandra; Barone, Carlo.
In: Current Treatment Options in Oncology, Vol. 17, No. 12, 59, 01.12.2016.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - From 2000 to 2016
T2 - Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
AU - D’Argento, Ettore
AU - Rossi, Sabrina
AU - Schinzari, Giovanni
AU - Strippoli, Antonia
AU - Basso, Michele
AU - Cassano, Alessandra
AU - Barone, Carlo
PY - 2016/12/1
Y1 - 2016/12/1
N2 - New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.
AB - New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.
KW - Antiangiogenic agents
KW - Immunotherapy
KW - Non-small-cell lung cancer
KW - Second line
UR - http://www.scopus.com/inward/record.url?scp=84992147341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992147341&partnerID=8YFLogxK
U2 - 10.1007/s11864-016-0437-x
DO - 10.1007/s11864-016-0437-x
M3 - Review article
AN - SCOPUS:84992147341
VL - 17
JO - Current Treatment Options in Oncology
JF - Current Treatment Options in Oncology
SN - 1527-2729
IS - 12
M1 - 59
ER -